Edge Advisors’s DexCom DXCM Stock Holding History

Edge Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-256	Closed	-$3K	–	885
2017 Q4	$3K	Buy	+256	New	+$3.33K	﹤0.01%	822

Other funds holding DXCM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Edge Advisors's DXCM Position: Q1 2018 in Review

Edge Advisors sold out of DexCom (DXCM) in Q1 2018, closing a stake of 256 shares — an estimated $3K sold.

Edge Advisors first reported a position in DXCM in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 276 funds tracked by Wall St. Rank hold DXCM as of Q1 2018.

Edge Advisors reported no remaining DexCom position as of Q1 2018 after selling out during the quarter.
Edge Advisors sold 256 DexCom shares in Q1 2018, an estimated $3K.
Edge Advisors first reported a position in DexCom in Q4 2017 and held it in 1 quarter.
Edge Advisors's DexCom position peaked at $3K in Q4 2017.
276 funds tracked by Wall St. Rank held DexCom as of Q1 2018.

Based on Edge Advisors's 13F filing for Q1 2018, filed 15 May 2018.